Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07501975

Effect of a Novel Colonoscopic Lavage Solution on Colonoscopy Quality

In recent years, with the continuous advancement of digestive endoscopy techniques, how to improve the adenoma detection rate (ADR) by optimizing endoscopic procedural details has become a research hotspot. Colonic spasm can lead to narrowing of the intestinal lumen, deepening of mucosal folds, and limited field of view, thereby affecting lesion exposure and reducing examination quality. Although traditional intravenous antispasmodic drugs (such as scopolamine) can alleviate intestinal spasms, they may cause side effects such as increased heart rate, blood pressure fluctuations, and other systemic adverse reactions. In contrast, menthol is a natural monoterpene compound derived from peppermint oil. It can inhibit L-type calcium channels on the cell membrane of smooth muscle through local application, thereby reducing intracellular calcium concentration and inducing smooth muscle relaxation. This helps to relieve intestinal spasms and patient discomfort during colonoscopy. On the other hand, simethicone, a commonly used defoaming agent, can reduce surface tension, eliminate foam, and improve mucosal visualization. Theoretically, combining antispasmodic menthol with defoaming simethicone may further optimize the visual field during colonoscopy and increase the ADR through a synergistic "antispasmodic + defoaming" mechanism. Therefore, this study plans to conduct a prospective randomized controlled trial to evaluate the antispasmodic effect, safety, and impact on the ADR of a novel irrigation solution (0.1% menthol combined with simethicone suspension) in colonoscopy, providing evidence-based medical support for optimizing endoscopic procedures.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age between 18 and 75 years, regardless of gender;
  • Scheduled to undergo colonoscopy (for screening, diagnostic, or follow-up purposes);
  • Adequate bowel preparation quality (Boston Bowel Preparation Scale score ≥ 6);
  • Voluntarily signed informed consent and able to cooperate with completing study-related assessments.

Exclusion criteria

  • Allergy to menthol, cyclodextrin, or related substances;
  • History of severe intestinal diseases (such as ulcerative colitis, Crohn's disease, intestinal perforation, intestinal obstruction, intestinal tumors, etc.);
  • Presence of severe dysfunction of vital organs such as the heart, liver, kidneys, or lungs, or coagulation disorders;
  • Pregnant or lactating women;
  • Use of anticholinergic drugs, calcium channel blockers, or other spasmolytic agents within one week prior to the examination;
  • Psychiatric disorders or cognitive impairment that prevent cooperation with the study;
  • History of contraindications to colonoscopy or serious adverse reactions during previous procedures.

Treatment and study plan

Endoscopic irrigation was performed using a novel irrigation solution

Diagnostic Test

Endoscopic irrigation was performed using a novel irrigation solution (0.1% menthol solution combined with simethicone aqueous suspension).

Irrigation was performed endoscopically using normal saline.

Diagnostic Test

Irrigation was performed endoscopically using normal saline.

Primary outcomes

  1. Adenoma detection rate (ADR).

    Time frame: Day 0

    ADR = (number of patients with at least one adenomatous polyp detected / total number of patients in the group) × 100%. Pathological diagnosis was used as the gold standard.

Secondary outcomes

  1. Incidence of intestinal spasm

    Time frame: Day 0

    The percentage of patients with an intestinal spasm score of 2 or 3 out of the total number of patients in the group.

    Intestinal spasm scoring criteria:

    Score 1 (Excellent): No spasm; the lumen opening is greater than or equal to two-thirds of the maximum diameter.

    Score 2 (Moderate): Moderate spasm; the lumen opening is less than two-thirds of the maximum diameter.

    Score 3 (Poor): Severe spasm; the oral-side lumen cannot be visualized.

    The maximum diameter is defined as the diameter of the intestinal lumen when fully distended.

  2. Spasm inhibition rate

    Time frame: Day 0

    The percentage of patients whose lumen opening exceeded two-thirds of the maximum diameter within 30 seconds after water injection irrigation, relative to the total number of patients in the group.

  3. Polyp detection rate (PDR)

    Time frame: Day 0

    PDR = (number of patients with at least one polyp detected / total number of patients in the group) × 100%.

Study contacts

Contact information is provided by the study sponsor or research team.

Jianning Yao

CONTACT

[email protected]

13733183434

Sponsors and collaborators

Lead sponsor

The First Affiliated Hospital of Zhengzhou University

Other

Registry information

Official study title

Effect of a Novel Colonoscopic Lavage Solution on Colonoscopy Quality: A Randomized Controlled Trial Evaluating Efficacy and Safety

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Mar 30, 2026
Registry last updated
Mar 30, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.